Rule 3.19A.2

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	: Elixinol Global Limited
ABN:	621 479 794

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Oliver Horn
Date of last notice	18 December 2020

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Indirect 2. Direct	
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Wellness Super Pty Ltd as trustee for Wellness Superannuation Fund (ABN 88 140 460 220), of which Mr Horn is a beneficiary.	
Date of change	31 January 2021	
No. of securities held prior to change	Indirect 266,471 ordinary fully paid shares  Direct 1,299,222 performance share rights	
Class	Ordinary Shares	
Number acquired	468,750	
Number disposed	Nil	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration	

01/01/2011 Appendix 3Y Page 1

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change	Indirect 266,471 ordinary fully paid shares
	Direct 468,750 ordinary fully paid shares 830,472 performance share rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Ordinary shares were issued following the vesting of Performance Rights issued with shareholder approval at the Company's 2020 Annual General Meeting on 30 July 2020 and pursuant to the Group CEO's Executive Agreement.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A	
Nature of interest	N/A	
Name of registered holder (if issued securities)	N/A	
Date of change	N/A	
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	N/A	
Interest acquired	N/A	
Interest disposed	N/A	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A	
Interest after change	N/A	

## Part 3 – +Closed period

Were the interests in the securities or contracts detailed	N/A
above traded during a +closed period where prior written	
clearance was required?	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

01/01/2011 Appendix 3Y Page 3

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.